Our Services
Medical Information
Helpful Resources
Published on: 5/22/2026
Multiple factors contribute to primary care doctors overprescribing steroids for uncontrolled CSU, including limited visit time, scarce specialist access, and comfort with steroid bursts that provide rapid relief over guideline-recommended antihistamines or biologics.
Important details below cover the risks of repeated steroid use, safer treatment alternatives, and practical steps you can take, so see below to understand more.
Chronic Spontaneous Urticaria (CSU), commonly known as hives, causes itchy welts or bumps on the skin that can last for six weeks or more. For patients struggling with persistent itching and discomfort, the quick relief that corticosteroids offer is tempting. Yet, guidelines from allergy and dermatology societies recommend antihistamines, omalizumab or other non-steroidal options as first-line therapies. So, why primary care doctors overprescribe steroids for CSU remains a pressing question.
Below, we explore the main factors driving this practice, outline potential risks, and offer practical steps you can take to manage CSU more safely and effectively.
Primary care visits are often limited to 10–15 minutes per patient. In that short window, doctors must:
When hives are severe, prescribing an oral steroid like prednisone can feel like the fastest way to ease suffering. Unfortunately, quick fixes may lead to long-term issues.
Access to allergy or dermatology specialists can be delayed by:
Rather than referring you promptly, a primary care doctor might reach for a steroid prescription as a "bridge" until specialist care is available. This bridges the gap but risks habitual use.
Many primary care providers (PCPs) are more accustomed to prescribing steroids for a range of inflammatory conditions, from asthma flares to joint pain. Reasons include:
By contrast, newer therapies like omalizumab (an injectable monoclonal antibody) require additional training, monitoring protocols, and paperwork, making them less accessible to busy PCPs.
Patients in distress often want rapid relief. Common scenarios:
Under patient pressure, a well-intentioned doctor may prescribe steroids to address symptoms immediately, believing this will buy time to adjust other treatments.
Despite updated guidelines from organizations like the American Academy of Allergy, Asthma & Immunology:
These gaps can perpetuate older habits rather than evidence-based care.
While short courses of steroids can help, extended or frequent use carries real dangers:
Understanding these risks empowers you to discuss alternative options with your doctor.
Before turning to steroids, experts recommend:
Second-Generation Antihistamines
Omalizumab (Xolair)
Other Add-On Therapies
Working with an allergist or dermatologist increases your chances of accessing these treatments safely.
Taking an active role in your care helps avoid unnecessary steroid exposure:
Communication is key. When discussing treatment:
A collaborative approach often leads to better outcomes and fewer unnecessary prescriptions.
Though most CSU cases aren't life-threatening, certain symptoms require urgent attention:
If you experience any of these, go to the closest emergency department or call emergency services. For non-emergency concerns, always speak to a doctor if symptoms worsen or you notice side effects from any medication.
By understanding the reasons behind steroid overuse and advocating for evidence-based care, you can manage CSU more safely and effectively over the long term.
(References)
* Zuberbier T, Abdul Latiff AH, Maurer M, Metz M, Rogala B, Roux S, Saini SS, Schneider-Burrus S, Siebenhaar F, Vestergaard C, Zazzali JL. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2022 Mar;77(3):739-766. doi: 10.1111/all.15090. Epub 2021 Sep 24. PMID: 34473215.
* Zampetti P, Campione E, Caposiena Caro RD, Celi A, Cicala G, D'Amico F, Esposito M, Farioli M, Fiaschetti M, Foti C, Galli M, Girolomoni G, Guanti G, Lazzaro F, Loconsole F, Lotti T, Manicardi C, Marinaro M, Patruno C, Quaglino P, Quarta G, Satolli F, Stingeni L, Vastarella M. Management of chronic spontaneous urticaria in the real-world setting: A European review. Front Med (Lausanne). 2022 Jul 11;9:920958. doi: 10.3389/fmed.2022.920958. PMID: 35911477.
* Smith D, Burls A, Taylor G, Thomas KS. Challenges in the management of chronic urticaria in general practice: a qualitative study of general practitioners' perspectives. Br J Gen Pract. 2018 Sep;68(674):e666-e673. doi: 10.3399/bjgp18X698308. PMID: 30127110.
* Grewal JS, Patanwala AE, Patanwala E. Long-term use of systemic corticosteroids for chronic urticaria: an observational study. J Drugs Dermatol. 2018 Jul 1;17(7):762-766. PMID: 30063704.
* Powell J, Rafee S, Khan M, Al-Hamwi F, Miah H, Kouris A, Flohr C, Irvine AD, Langan SM. Patient experience of chronic spontaneous urticaria in the UK: a quantitative and qualitative study. Br J Dermatol. 2022 Jun;186(6):1041-1049. doi: 10.1111/bjd.21043. Epub 2022 Mar 9. PMID: 33733479.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.